Evan David Seigerman
Stock Analyst at BMO Capital
(2.48)
# 2,013
Out of 4,883 analysts
44
Total ratings
27.5%
Success rate
0.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $19.75 | +31.65% | 2 | Jun 12, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $800 → $600 | $547.74 | +9.54% | 7 | Jun 2, 2025 | |
| MRUS Merus | Maintains: Outperform | $96 → $110 | $53.33 | +106.26% | 1 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $21.24 | +31.83% | 1 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $7.90 | +26.58% | 1 | May 5, 2025 | |
| NVO Novo Nordisk | Downgrades: Market Perform | $105 → $64 | $69.82 | -8.34% | 6 | Apr 17, 2025 | |
| MRK Merck & Co. | Maintains: Market Perform | $105 → $96 | $82.39 | +16.52% | 4 | Feb 5, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $208 → $215 | $190.75 | +12.71% | 7 | Feb 3, 2025 | |
| AMGN Amgen | Maintains: Outperform | $362 → $346 | $296.85 | +16.56% | 4 | Jan 29, 2025 | |
| REPL Replimune Group | Maintains: Outperform | $18 → $27 | $9.55 | +182.72% | 3 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $20.44 | +389.24% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $25.32 | +42.18% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $4.99 | -39.88% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $779.28 | -49.18% | 1 | Sep 6, 2022 |
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $19.75
Upside: +31.65%
Regeneron Pharmaceuticals
Jun 2, 2025
Maintains: Outperform
Price Target: $800 → $600
Current: $547.74
Upside: +9.54%
Merus
May 23, 2025
Maintains: Outperform
Price Target: $96 → $110
Current: $53.33
Upside: +106.26%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $21.24
Upside: +31.83%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $7.90
Upside: +26.58%
Novo Nordisk
Apr 17, 2025
Downgrades: Market Perform
Price Target: $105 → $64
Current: $69.82
Upside: -8.34%
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105 → $96
Current: $82.39
Upside: +16.52%
AbbVie
Feb 3, 2025
Maintains: Outperform
Price Target: $208 → $215
Current: $190.75
Upside: +12.71%
Amgen
Jan 29, 2025
Maintains: Outperform
Price Target: $362 → $346
Current: $296.85
Upside: +16.56%
Replimune Group
Jan 22, 2025
Maintains: Outperform
Price Target: $18 → $27
Current: $9.55
Upside: +182.72%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $20.44
Upside: +389.24%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $25.32
Upside: +42.18%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $4.99
Upside: -39.88%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $779.28
Upside: -49.18%